Laurus Labs Share Price Target 2025, 2030, 2040, 2050
Laurus Labs Limited was established in 2005. The company makes medicines and drugs for chronic diseases like HIV, Cancer, heart attack etc. The company situated in India, does business globally as it provides the best and most accurate medicine as per requirements. In this article, we will study this company in depth.
What is Laurus Labs Ltd NSE: LAURUSLABS?
Laurus Labs Limited is an Indian pharmaceutical company that makes and sells medicines and drug ingredients. The company was established in 2005 and is situated in Hyderabad, India. It mainly makes medicines for critical diseases like cancer, HIV, heart problems, and stomach issues. The company also helps other companies develop and manufacture medicines from the early stages to large-scale production. The company is known for its top-quality medicine and has customers globally.
Laurus Labs Share Price Target Tomorrow
The stock is in a bullish trend in the short term. It took support and training to touch its all-time high in the upcoming time, so for some days you will notice some bullish move in this stock and could be profitable for short-term investment.
| Day | Minimum Price | Maximum Price |
| Tomorrow | -20 | +29 |
Laurus Labs Share Price Target 2025
The company started by setting up its research centre, where it filed its first patent for making cancer treatment ingredients with an Indian pharmaceutical company. After that, it soon got agreements with multinational companies and set up its first manufacturing unit.
It then filed its first Drug Master File, started production, and delivered its first product to the U.S. Laurus Labs’ research Centre was recognized by DSIR, launched four nutritional chemicals, entered the European market, and signed a global deal to make and sell ARV(medications used to treat HIV/AIDS.) products. By 2025, its share price target would be ₹900.
In 2025, its price target would be between ₹370 to ₹900, according to our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 370 | 900 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 480 | 640 |
| February | 458 | 722 |
| March | 390 | 530 |
| April | 370 | 510 |
| May | 438 | 578 |
| June | 456 | 610 |
| July | 597 | 680 |
| August | 638 | 710 |
| September | 657 | 738 |
| October | 680 | 790 |
| November | 745 | 856 |
| December | 810 | 900 |
Laurus Labs Share Price Target 2026
The company mainly expanding API production which will help the company’s growth in present as well as in future. API means Active Pharmaceutical Ingredient, which is the main ingredient in a drug that produces the intended effects. This company develop and produce APIs, which are used to make medicines. Also, it works to improve its position in the CRAMS market and bringing in new products will likely help its success. In 2026, its share price target would be ₹1060.
In 2026, its price target would be between ₹470 to ₹1060 to our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 470 | 1060 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 810 | 918 |
| February | 741 | 768 |
| March | 643 | 690 |
| April | 541 | 574 |
| May | 470 | 510 |
| June | 490 | 578 |
| July | 545 | 637 |
| August | 590 | 687 |
| September | 647 | 790 |
| October | 730 | 887 |
| November | 860 | 973 |
| December | 920 | 1060 |
Share Price Target 2027
This company is expected to keep growing in the pharmaceutical industry, especially with its focus on important medicines like cancer and HIV treatments. The company is expanding its business globally, and its strong efforts in research and development could lead to growth. But also market conditions and competition in the healthcare industry might present challenges, the company’s dedication to innovation and making high-quality medicines will likely help its share price continue to rise. In 2027 its share price target would be ₹1220 as per our analysis.
By our prediction, its share price would be between ₹590 to ₹1220 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 590 | 1220 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 920 | 1079 |
| February | 810 | 865 |
| March | 710 | 757 |
| April | 632 | 678 |
| May | 590 | 655 |
| June | 628 | 725 |
| July | 678 | 780 |
| August | 738 | 860 |
| September | 823 | 968 |
| October | 928 | 1056 |
| November | 1011 | 1180 |
| December | 1145 | 1220 |
Share Price Target 2028
The company’s work in increasing its production and growing its market share in making Active Pharmaceutical Ingredients will be important for its stock performance. The company’s partnerships and new products can help it become stronger in the industry. By continuing to enter new markets and investing in advanced research, Laurus Labs is expected to attract more investors and keep growing steadily. So in 2028, its share price target would be ₹1360 as per our analysis.
By our prediction, its share price would be between ₹680 to ₹1360 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 680 | 1360 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1145 | 1238 |
| February | 1011 | 1046 |
| March | 932 | 975 |
| April | 866 | 879 |
| May | 768 | 789 |
| June | 680 | 762 |
| July | 738 | 860 |
| August | 790 | 978 |
| September | 910 | 1078 |
| October | 1038 | 1176 |
| November | 1127 | 1278 |
| December | 1245 | 1360 |
Share Price Target 2029
Its strong position in the HIV/AIDS treatment market and partnerships with international companies will likely improve its reputation and profits. The company is expected to see long-term benefits from its investments in technology, production, and research. If the company continues to take advantage of the growing healthcare demand and adjusts to new regulations, its share price is likely to rise, showing its strong market presence and good financial performance. In 2029, its share price target would be ₹1470 as per our analysis.
By our prediction, its share price would be between ₹770 to ₹1470 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 770 | 1470 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1245 | 1387 |
| February | 1121 | 1174 |
| March | 1021 | 1078 |
| April | 910 | 955 |
| May | 828 | 845 |
| June | 770 | 830 |
| July | 790 | 858 |
| August | 825 | 990 |
| September | 964 | 1172 |
| October | 1090 | 1287 |
| November | 1256 | 1390 |
| December | 1356 | 1470 |
Laurus Labs Share Price Target 2030
It makes a variety of products including APIs and advanced ingredients for important health treatments, beauty products, and enzyme solutions for industrial use. The company is known for its new ideas, high quality, and focus on customer needs. Its focus on research and development has helped it earn many patents, making it a top company in the industry. By 2030, its share price target would be ₹1694 as per technical analysis and the company’s status.
In 2030, its share price would be between ₹900 to ₹1694 as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 900 | 1694 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1356 | 1488 |
| February | 1221 | 1264 |
| March | 1120 | 1138 |
| April | 1010 | 1046 |
| May | 900 | 990 |
| June | 950 | 1070 |
| July | 987 | 1125 |
| August | 1057 | 1258 |
| September | 1190 | 1385 |
| October | 1278 | 1458 |
| November | 1312 | 1588 |
| December | 1543 | 1694 |
Share Price Target 2040
The company has shown consistent growth in past, which successfully provides a good amount of return to its long-term investors. The company’s ability to adjust itself to market challenges reflects its strong position in the pharmaceutical industry. With technological advancements and increasing global demand, the company working hard. The company is well-positioned to take advantage of increasing and has the potential for expansion the company in the coming years. In 2040, its share price target would be ₹3541 to the expert’s analysis.
As per our experts, its share price would be between ₹2845 to ₹3541 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 2845 | 3541 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2845 | 2974 |
| February | 2870 | 2997 |
| March | 2960 | 3068 |
| April | 3010 | 3099 |
| May | 3065 | 3128 |
| June | 3090 | 3165 |
| July | 3128 | 3180 |
| August | 3156 | 3256 |
| September | 3210 | 3378 |
| October | 3346 | 3459 |
| November | 3410 | 3519 |
| December | 3490 | 3541 |
Share Price Target 2050
It makes complex ingredients for important medicines and develops final products, especially for ARVs and cancer treatments. The company also provides research and manufacturing services to global pharmaceutical companies. The company holds a strong position in the ARV market, which is expected to grow due to increasing demand worldwide. Also, Its partnerships with international pharmaceutical companies boost its market presence and reputation. In 2050, its share price target would be ₹6635 as per our expert’s prediction.
By 2050, its share price will be between ₹5841 to ₹6635 as per our expert team.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 5841 | 6635 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 5841 | 5974 |
| February | 5876 | 6030 |
| March | 5968 | 6054 |
| April | 6010 | 6146 |
| May | 6121 | 6187 |
| June | 6146 | 6232 |
| July | 6198 | 6378 |
| August | 6257 | 6457 |
| September | 6378 | 6480 |
| October | 6423 | 6510 |
| November | 6456 | 6580 |
| December | 6538 | 6635 |
Should I Buy Laurus Labs Stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 370 | 900 |
| 2026 | 470 | 1060 |
| 2027 | 590 | 1220 |
| 2028 | 680 | 1360 |
| 2029 | 770 | 1470 |
| 2030 | 900 | 1694 |
| 2040 | 2845 | 3541 |
| 2050 | 5841 | 6635 |
The share price has been continuously rising over the last six months, showing that investors trust the stock. it works in fast-growing healthcare areas and has a strong global presence. They have improved their manufacturing and offer a good range of generic active pharmaceutical ingredients (APIs). Also, the company records an increase in sales and profits compared to last year, indicating the company is making the most of market opportunities. Overall, many investors might find Laurus Labs a good investment choice.
Laurus Labs Earning Results
| Mcap Full (Cr.) | 24,283.74 |
| Turnover (Cr.) | 1.98 |
| TTQ (Lakh) | 0.44 |
| EPS (TTM) | 4.44 |
| CEPS (TTM) | 10.97 |
| ROE | 5.69 |
| Face Value | 2.00 |
| NPM % | 2.58 |
| OPM % | 15.28 |
| Cash EPS | 2.22 |
| EPS | 0.53 |
| Net Profit(Cr.) | 28.78 |
| Revenue(Cr.) | 1,116.93 |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 169.25 | 6.09 | 0.17% | 51.50 | 6.58 | 0.48% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| Laurus Labs Ltd | 156.24 | 6.09 | 0.17% |
| Sun Pharmaceutical Industries Ltd | 47.53 | 6.78 | 0.71% |
| Cipla Ltd | 29.86 | 4.59 | 0.85% |
| Torrent Pharmaceuticals Ltd | 69.32 | 16.75 | 0.83% |
Is Laurus Labs Stock Good to Buy? (Bull case & Bear case)
Bull Case:
- The company offers many different types of medicines, which helps protect it from risks if one product doesn’t do well.
- It is growing its factories and entering new markets, which could lead to more sales.
- It has been making more money every year, the past performance looks much good for this company.
- The pharmaceutical market is expected to grow because more people need healthcare.
- The company invests in research to create new and better products, helping it stay competitive.
Bear Case:
- Many other companies also make generic drugs, which can limit their profits.
- If the company depends too much on a few products, any drop in demand could create problems.
- Economic Factors: Changes in the economy, like currency shifts or healthcare policies, could affect sales.
- The drug industry has strict rules. If Laurus Labs doesn’t follow them, it could face serious issues.
Conclusion
In this article, we have given you all the main information about Laurus Labs. The company doing very well in its sector they also do business globally. Talking about its finances, it gave continuous good returns to its long-term Investors. So if you plan to invest or want to know more about this company then you should read the whole article to get a proper view for investing here or not.
FAQs
No, the debt-to-equity ratio for Laurus Labs is 0.612, which is higher than the average of 0.530 over the last five years.
As of 22nd October 2024, its P/E ratio is 169.02.
Satyanarayana Chava.
